Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro - PubMed (original) (raw)
Affiliations
- PMID: 12168112
Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro
Shouji Shimoyama et al. Int J Oncol. 2002 Sep.
Abstract
We investigated supra-additive cytotoxic effects of 5-fluorouracil (5FU) on gastric and colon cancer cells with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in vitro. p53 wild- and mutant-type gastric and colon cancer cell lines were treated by 5FU alone, TRAIL alone, and a combination of 5FU and TRAIL, and cell viability after each treatment was determined by MTT assay. The p53 wild-type cells were more sensitive to 5FU alone or to TRAIL alone than p53 mutant-type cells. The cell growth inhibitory effects of the combined treatment were supra-additive and more significant in proportion to the increasing concentrations of TRAIL as compared with 5FU alone both in p53 wild- and mutant-type cells. Furthermore, TRAIL could cause a decrease in 5FU IC(50) to within the range of clinically relevant doses, particularly in p53 wild-type cells. This is the first demonstration of the supra-additive antitumor activity of 5FU with TRAIL on gastric cancer cells, giving evidence that TRAIL can reduce the requirement for 5FU that ultimately results in minimizing risks for systemic side effects while increasing the antitumor activity of 5FU, suggesting the clinical applicability of this combination for gastric and colon cancers.
Similar articles
- Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A. Ravi R, et al. Cancer Res. 2004 Dec 15;64(24):9105-14. doi: 10.1158/0008-5472.CAN-04-2488. Cancer Res. 2004. PMID: 15604280 - Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.
Xu LH, Deng CS, Zhu YQ, Liu SQ, Liu DZ. Xu LH, et al. World J Gastroenterol. 2003 Jun;9(6):1241-5. doi: 10.3748/wjg.v9.i6.1241. World J Gastroenterol. 2003. PMID: 12800232 Free PMC article. - Potential and caveats of TRAIL in cancer therapy.
Held J, Schulze-Osthoff K. Held J, et al. Drug Resist Updat. 2001 Aug;4(4):243-52. doi: 10.1054/drup.2001.0208. Drug Resist Updat. 2001. PMID: 11991679 Review. - Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3.
Tomoda A, Miyazawa K, Tabuchi T. Tomoda A, et al. Int J Mol Sci. 2013 Aug 28;14(9):17573-83. doi: 10.3390/ijms140917573. Int J Mol Sci. 2013. PMID: 23989604 Free PMC article. Review.
Cited by
- Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. van Geelen CM, et al. Br J Cancer. 2003 Jul 21;89(2):363-73. doi: 10.1038/sj.bjc.6601065. Br J Cancer. 2003. PMID: 12865931 Free PMC article. - Synthesis, characterisation and anti-tumour activity of biopolymer based platinum nanoparticles and 5-fluorouracil loaded platinum nanoparticles.
Godugu D, Beedu SR. Godugu D, et al. IET Nanobiotechnol. 2019 May;13(3):282-292. doi: 10.1049/iet-nbt.2018.5171. IET Nanobiotechnol. 2019. PMID: 31053691 Free PMC article. - Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.
Blanchet A, Bourgmayer A, Kurtz JE, Mellitzer G, Gaiddon C. Blanchet A, et al. Cancers (Basel). 2021 Feb 22;13(4):916. doi: 10.3390/cancers13040916. Cancers (Basel). 2021. PMID: 33671606 Free PMC article. Review. - Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis.
Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M. Hague A, et al. Br J Cancer. 2005 Feb 28;92(4):736-42. doi: 10.1038/sj.bjc.6602387. Br J Cancer. 2005. PMID: 15685228 Free PMC article. - Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma.
Lee KH, Lim SW, Kim HG, Kim DY, Ryu SY, Joo JK, Kim JC, Lee JH. Lee KH, et al. Langenbecks Arch Surg. 2009 Jul;394(4):661-70. doi: 10.1007/s00423-009-0484-x. Epub 2009 Apr 7. Langenbecks Arch Surg. 2009. PMID: 19350268
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous